Cephalon's Nuvigil for shift work holds up well in post-approval study
This article was originally published in Scrip
Executive Summary
Cephalon has reported positive top-line results from a post-approval (Phase IV) clinical trial of its narcolepsy drug Nuvigil (armodafinil) in patients experiencing excessive sleepiness associated with shift work disorder – the largest trial ever conducted in this patient group, with more than 380 patients randomised to either study drug or placebo.